OptimizeRx Corp: Form 10-Q for the period ended Jun 30, 2026
Filed with the SEC on Aug 13, 2026 and accepted by EDGAR at Aug 13, 2026, 20:06 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2026-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2026-04-01 to 2026-06-30 | $20.5m | us-gaap:Revenues |
| Revenue | 6 months2026-01-01 to 2026-06-30 | $40.3m | us-gaap:Revenues |
| Cost of revenue | 3 months2026-04-01 to 2026-06-30 | $4.8m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2026-01-01 to 2026-06-30 | $9.7m | us-gaap:CostOfRevenue |
| Research and development | 3 months2026-04-01 to 2026-06-30 | $3.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2026-01-01 to 2026-06-30 | $6.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2026-04-01 to 2026-06-30 | −$88.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2026-01-01 to 2026-06-30 | $308.0k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2026-04-01 to 2026-06-30 | $1.1m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2026-01-01 to 2026-06-30 | $2.3m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2026-04-01 to 2026-06-30 | −$393.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2026-01-01 to 2026-06-30 | −$542.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2026-04-01 to 2026-06-30 | −$703.0k | us-gaap:NetIncomeLoss |
| Net income | 6 months2026-01-01 to 2026-06-30 | −$1.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2026-04-01 to 2026-06-30 | −$0.04 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2026-01-01 to 2026-06-30 | −$0.06 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2026-04-01 to 2026-06-30 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2026-01-01 to 2026-06-30 | −$0.06 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2026-04-01 to 2026-06-30 | 18,785,596 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2026-01-01 to 2026-06-30 | 18,773,638 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2026-01-01 to 2026-06-30 | $8.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2026-01-01 to 2026-06-30 | $56.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2026-06-30 | $24.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2026-06-30 | $54.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2026-06-30 | $164.3m | us-gaap:Assets |
| Current liabilities | At period end2026-06-30 | $9.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2026-06-30 | $33.2m | us-gaap:Liabilities |
| Long-term debt | At period end2026-06-30 | $17.8m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2026-06-30 | $1.3m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2026-06-30 | $131.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001448431-26-000016. Last ingested by Listed: Oct 24, 2026, 15:08 ET. Listed shows no prices and gives no investment advice.